Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter…
News
Airway Therapeutics secures $50m for Phase IIb/III zelpultide alfa trial
Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex
Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data
Liminatus Pharma selects Synex to advance CAR-T trial
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
Industry and federally backed cancer trials diverge in goals, analysis finds
Analysts praise intismeran’s landmark Phase III win, look to further data
